Cargando…
Facilitating a More Efficient Commercial Review Process for Pediatric Drugs and Biologics
Over the past two decades, the biopharmaceutical industry has seen unprecedented expansion and innovation in concert with significant technological advancements. While the industry has experienced marked growth, the regulatory system in the United States still operates at a capacity much lower than...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
0201
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5871948/ https://www.ncbi.nlm.nih.gov/pubmed/29271878 http://dx.doi.org/10.3390/diseases6010002 |
_version_ | 1783309728710918144 |
---|---|
author | Rykhus, Ryan D. Shepard, Zachary V. Young, Alix Frisby, Hadley Calder, Kailee A. Coon, Collin M. Falk, Justin A. McAndrews, Sydney R. Turner, Aspen Chang, Christina Michelsohn, Johanna Petch, Raegan Dieker, Sarah M. Markworth, Benjamin H. Alamo-Perez, Kevin Hosack, Aaron J. Berg, Jacob M. Schmidt, Christian Storsberg, Joachim Brown, Mark A. |
author_facet | Rykhus, Ryan D. Shepard, Zachary V. Young, Alix Frisby, Hadley Calder, Kailee A. Coon, Collin M. Falk, Justin A. McAndrews, Sydney R. Turner, Aspen Chang, Christina Michelsohn, Johanna Petch, Raegan Dieker, Sarah M. Markworth, Benjamin H. Alamo-Perez, Kevin Hosack, Aaron J. Berg, Jacob M. Schmidt, Christian Storsberg, Joachim Brown, Mark A. |
author_sort | Rykhus, Ryan D. |
collection | PubMed |
description | Over the past two decades, the biopharmaceutical industry has seen unprecedented expansion and innovation in concert with significant technological advancements. While the industry has experienced marked growth, the regulatory system in the United States still operates at a capacity much lower than the influx of new drug and biologic candidates. As a result, it has become standard for months or even years of waiting for commercial approval by the U.S. Food and Drug Administration. These regulatory delays have generated a system that stifles growth and innovation due to the exorbitant costs associated with awaiting approval from the nation’s sole regulatory agency. The recent re-emergence of diseases that impact pediatric demographics represents one particularly acute reason for developing a regulatory system that facilitates a more efficient commercial review process. Herein, we present a range of initiatives that could represent early steps toward alleviating the delays in approving life-saving therapeutics. |
format | Online Article Text |
id | pubmed-5871948 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 0201 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-58719482018-03-29 Facilitating a More Efficient Commercial Review Process for Pediatric Drugs and Biologics Rykhus, Ryan D. Shepard, Zachary V. Young, Alix Frisby, Hadley Calder, Kailee A. Coon, Collin M. Falk, Justin A. McAndrews, Sydney R. Turner, Aspen Chang, Christina Michelsohn, Johanna Petch, Raegan Dieker, Sarah M. Markworth, Benjamin H. Alamo-Perez, Kevin Hosack, Aaron J. Berg, Jacob M. Schmidt, Christian Storsberg, Joachim Brown, Mark A. Diseases Communication Over the past two decades, the biopharmaceutical industry has seen unprecedented expansion and innovation in concert with significant technological advancements. While the industry has experienced marked growth, the regulatory system in the United States still operates at a capacity much lower than the influx of new drug and biologic candidates. As a result, it has become standard for months or even years of waiting for commercial approval by the U.S. Food and Drug Administration. These regulatory delays have generated a system that stifles growth and innovation due to the exorbitant costs associated with awaiting approval from the nation’s sole regulatory agency. The recent re-emergence of diseases that impact pediatric demographics represents one particularly acute reason for developing a regulatory system that facilitates a more efficient commercial review process. Herein, we present a range of initiatives that could represent early steps toward alleviating the delays in approving life-saving therapeutics. MDPI 02017-12-22 /pmc/articles/PMC5871948/ /pubmed/29271878 http://dx.doi.org/10.3390/diseases6010002 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Communication Rykhus, Ryan D. Shepard, Zachary V. Young, Alix Frisby, Hadley Calder, Kailee A. Coon, Collin M. Falk, Justin A. McAndrews, Sydney R. Turner, Aspen Chang, Christina Michelsohn, Johanna Petch, Raegan Dieker, Sarah M. Markworth, Benjamin H. Alamo-Perez, Kevin Hosack, Aaron J. Berg, Jacob M. Schmidt, Christian Storsberg, Joachim Brown, Mark A. Facilitating a More Efficient Commercial Review Process for Pediatric Drugs and Biologics |
title | Facilitating a More Efficient Commercial Review Process for Pediatric Drugs and Biologics |
title_full | Facilitating a More Efficient Commercial Review Process for Pediatric Drugs and Biologics |
title_fullStr | Facilitating a More Efficient Commercial Review Process for Pediatric Drugs and Biologics |
title_full_unstemmed | Facilitating a More Efficient Commercial Review Process for Pediatric Drugs and Biologics |
title_short | Facilitating a More Efficient Commercial Review Process for Pediatric Drugs and Biologics |
title_sort | facilitating a more efficient commercial review process for pediatric drugs and biologics |
topic | Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5871948/ https://www.ncbi.nlm.nih.gov/pubmed/29271878 http://dx.doi.org/10.3390/diseases6010002 |
work_keys_str_mv | AT rykhusryand facilitatingamoreefficientcommercialreviewprocessforpediatricdrugsandbiologics AT shepardzacharyv facilitatingamoreefficientcommercialreviewprocessforpediatricdrugsandbiologics AT youngalix facilitatingamoreefficientcommercialreviewprocessforpediatricdrugsandbiologics AT frisbyhadley facilitatingamoreefficientcommercialreviewprocessforpediatricdrugsandbiologics AT calderkaileea facilitatingamoreefficientcommercialreviewprocessforpediatricdrugsandbiologics AT cooncollinm facilitatingamoreefficientcommercialreviewprocessforpediatricdrugsandbiologics AT falkjustina facilitatingamoreefficientcommercialreviewprocessforpediatricdrugsandbiologics AT mcandrewssydneyr facilitatingamoreefficientcommercialreviewprocessforpediatricdrugsandbiologics AT turneraspen facilitatingamoreefficientcommercialreviewprocessforpediatricdrugsandbiologics AT changchristina facilitatingamoreefficientcommercialreviewprocessforpediatricdrugsandbiologics AT michelsohnjohanna facilitatingamoreefficientcommercialreviewprocessforpediatricdrugsandbiologics AT petchraegan facilitatingamoreefficientcommercialreviewprocessforpediatricdrugsandbiologics AT diekersarahm facilitatingamoreefficientcommercialreviewprocessforpediatricdrugsandbiologics AT markworthbenjaminh facilitatingamoreefficientcommercialreviewprocessforpediatricdrugsandbiologics AT alamoperezkevin facilitatingamoreefficientcommercialreviewprocessforpediatricdrugsandbiologics AT hosackaaronj facilitatingamoreefficientcommercialreviewprocessforpediatricdrugsandbiologics AT bergjacobm facilitatingamoreefficientcommercialreviewprocessforpediatricdrugsandbiologics AT schmidtchristian facilitatingamoreefficientcommercialreviewprocessforpediatricdrugsandbiologics AT storsbergjoachim facilitatingamoreefficientcommercialreviewprocessforpediatricdrugsandbiologics AT brownmarka facilitatingamoreefficientcommercialreviewprocessforpediatricdrugsandbiologics |